Morepen Labs Q2 Revenue Hits Record ₹755 Cr, EBITDA Surges 273%

Morepen Laboratories reported a record second quarter revenue of Rs. 755 Cr, an 81% increase year-on-year, for Q2 FY27. EBITDA surged by 273% to Rs. 132 Cr, with a significant expansion in EBITDA margin to 17.45%. Profit After Tax (PAT) grew by 117% to Rs. 89 Cr. This performance was driven by the scale-up of commercial CDMO supplies, an improved business mix, and higher operating leverage. For the first half of FY27, revenue increased by 57% to Rs. 1330 Cr, and EBITDA rose by 243% to Rs. 220 Cr. The company highlighted the growing contribution of its CDMO business, which reached Rs. 253 Cr in Q2 FY27, representing 52% of API + CDMO revenue. Exports also saw substantial growth, up 131% to Rs. 397 Cr in Q2 FY27 and up 122% to Rs. 654 Cr in H1 FY27. The company is also expanding its CDMO capacity, with the next phase targeting 800 KL by Q2 FY28.